Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers

International Journal of Cancer

Volumn 88, Issue 1, 2000, Pages 12-20

  Conejo, J R ^a   Kleeff, J ^a   Koliopanos, A ^a   Matsuda, K ^b   Zhu, Z W ^a   Goecke, H ^a   Bicheng, N ^a   Zimmermann, A ^a   Korc, M ^b   Friess, H ^a   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOHEPARAN SULFATE; SYNDECAN;

ACINAR CELL; ADULT; AGED; ARTICLE; CELL STRUCTURE; CELL SURFACE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; BLOTTING, NORTHERN; CHRONIC DISEASE; COLONIC NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROTEOGLYCANS; RNA, MESSENGER; STOMACH NEOPLASMS; SYNDECAN-1; SYNDECANS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0033856662     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T     Document Type: Article

References (44)

1. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF
2. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors
3. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas
4. Transcriptional activation of the syndecan-1 promoter by the Wilm's tumor protein WT1
5. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence
6. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation
7. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies
8. Growth factors induce 3T3 cells to express bFGF-binding syndecan
9. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity
10. Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis
11. KAI1 is unchanged in metastatic and nonmetastatic esophageal and gastric cancers
12. Real time quantitative PCR
13. Altered proliferative and metastatic potential associated with increased expression of syndecan-1
14. The role of syndecan-1 in malignancies
15. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck
16. Transcriptional regulation of syndecan-1 expression by growth factors
17. The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner
18. Syndecan, a regulator of cell behaviour, is lost in malignant transformation
19. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2
20. A dual receptor system is required for basic fibroblast growth factor activity
21. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer
22. Role of growth factors in pancreatic cancer
23. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
24. Human prostate carcinoma cells produce extracellular heparanase
25. Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome
26. Syndecan-1 expression is down-regulated during myoblast terminal differentiation. Modulation by growth factors and retinoic acid
27. Production of heparanase by normal and neoplastic murine B-lymphocytes
28. Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes
29. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions
30. Suppression of tumor cell growth by syndecan-1 ectodomain
31. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential
32. Heparan sulfate proteoglycan expression in human lung-cancer cells
33. Cancer cell heparanase activity associated with invasion and metastasis
34. Syndecan-1: A new prognostic marker in laryngeal cancer
35. Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells
36. Molecular interactions of the syndecan core proteins
37. Syndecan family of cell surface proteoglycans: Developmentally regulated receptors for extracellular effector molecules
38. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells
39. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation
40. Functional characterization of mouse syndecan-1 promoter
41. Inhibition of tumor metastasis by heparanase-inhibiting species of heparin
42. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
43. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
44. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor